We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
OXLUMO (Medison Pharma Australia Pty Ltd)
Product name
OXLUMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
154 (175 working days)
Active ingredients
lumasiran sodium
Registration type
NCE/NBE
Indication
Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) in all agegroups.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.